Literature DB >> 3730611

Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations.

M H Rosove, M Ismail, B J Koziol, A Runge, C K Kasper.   

Abstract

We utilized a kaolin-activated partial thromboplastin time (APTT) using rabbit brain phospholipid, in which the capacity of a fourfold increased "high" phospholipid concentration (PC) to normalize the abnormal "standard" PC-APTT in patients with lupus anticoagulants is assessed. This system was also used to measure factors VIIIC, IX, and XI. The tissue thromboplastin inhibition test (TTI), a prothrombin time system in which the activity of a lupus anticoagulant is unmasked by the use of dilute thromboplastin, was simultaneously evaluated. Test sensitivity was defined by results on 31 consecutive patients with standard PC-APTT inhibitors and no bleeding tendency. Specificity was based on 94 patients with various other coagulopathies, including coagulation factor inhibitors, severe congenital factor deficiencies, hepatic insufficiency, and warfarin and heparin treatment. Twenty-one patients with lupus erythematosus and standard PC-APTT results within normal limits were also tested. Sensitivity of the APTT system was superior to that of the TTI (97% v 58%); high PC normalized clotting time ratios and factor levels. Positive results were common with both assays in the group of 20 heparinized patients. The APTT system had superior specificity in remaining cases; there were no positive tests among 74 patients. The lupus erythematosus group had a significant decrease in the clotting time ratio with high PC, indicating that low-level lupus anticoagulants are quite prevalent in this group. The kaolin clotting time using rabbit brain phospholipid in standard and high concentrations is a simple, sensitive, and specific technique for diagnosis of lupus anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3730611

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Influence of the lupus anticoagulant on clotting tests.

Authors:  J Vermylen; J Arnout
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 2.  Detection of lupus anticoagulants.

Authors:  M H Horellou; M M Samama
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

3.  Multiple autoantibody production in a patient with splenic lymphoma.

Authors:  M Sawamura; S Yamaguchi; H Murakami; H Amagai; T Matsushima; J Tamura; T Naruse; J Tsuchiya
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

4.  The Taipan snake venom time: a new test for lupus anticoagulant.

Authors:  A M Rooney; T McNally; I J Mackie; S J Machin
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

5.  Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations.

Authors:  K Padmakumar; R R Singh; R Rai; A N Malaviya; A K Saraya
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

6.  Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Authors:  R H Derksen; P Hasselaar; L Blokzijl; F H Gmelig Meyling; P G De Groot
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

7.  Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome.

Authors:  Sudha Visvanathan; Jamie K Scott; Kwan-Ki Hwang; Michelle Banares; Jennifer M Grossman; Joan T Merrill; John FitzGerald; Reginald U Chukwuocha; Betty P Tsao; Bevra H Hahn; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2003-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.